Scholarlink

<p>Iron overload (IO) is a harmful condition in humans that promotes oxidative damage to DNA and lipids. As IO has been associated with the onset of neurodegenerative diseases (NDs), chelation therapy has been extensively used for treating IO and considered potentially suitable for NDs treatment. Desferrioxamine (DFO) presents high affinity and selectivity for iron(III), however, its clinical use as chelator is limited due to its low cell permeability. To circumvent this limitation, synthetic routes and conditions were selected for conjugating DFO to 5-aminolevulinic acid (5-ALA) or γ-aminobutyric acid (GABA), non-proteinogenic amino acids previously reported as permeable to the blood–brain barrier (BBB). Once obtained and purified, the conjugates 5-ALA-DFO and GABA-DFO were characterized by LC/ESI–MS and <sup>1</sup>H and <sup>13</sup>C NMR. Both exhibited iron binding abilities comparable to that of DFO, displayed identical antioxidant activity, weak interactions with human serum albumin, and were unable to remove iron from transferrin (Tf). Based on DFT calculations, a theoretical model was developed that allows to predict the efficiency of iron chelation with DFO and its conjugates, in good agreement with experimental results. In assays with human colorectal adenocarcinoma (Caco-2) cells, a model for the blood–brain barrier (BBB), both chelators were non-toxic, and unlike DFO or 5-ALA-DFO, GABA-DFO was able to bind intracellular iron. Altogether, these results demonstrate that the chemical conjugation proposed here was highly effective and that GABA-DFO is a promising intracellular iron chelator.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Conjugates of desferrioxamine with 5-aminolevulinic or γ-aminobutyric acid: synthesis, theoretical studies, iron-chelating ability, and penetration in human Caco-2 cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Ernani Lacerda,
  • Vasilii D. Khripun,
  • M. Teresa Machini,
  • Breno Pannia Espósito

摘要

Iron overload (IO) is a harmful condition in humans that promotes oxidative damage to DNA and lipids. As IO has been associated with the onset of neurodegenerative diseases (NDs), chelation therapy has been extensively used for treating IO and considered potentially suitable for NDs treatment. Desferrioxamine (DFO) presents high affinity and selectivity for iron(III), however, its clinical use as chelator is limited due to its low cell permeability. To circumvent this limitation, synthetic routes and conditions were selected for conjugating DFO to 5-aminolevulinic acid (5-ALA) or γ-aminobutyric acid (GABA), non-proteinogenic amino acids previously reported as permeable to the blood–brain barrier (BBB). Once obtained and purified, the conjugates 5-ALA-DFO and GABA-DFO were characterized by LC/ESI–MS and 1H and 13C NMR. Both exhibited iron binding abilities comparable to that of DFO, displayed identical antioxidant activity, weak interactions with human serum albumin, and were unable to remove iron from transferrin (Tf). Based on DFT calculations, a theoretical model was developed that allows to predict the efficiency of iron chelation with DFO and its conjugates, in good agreement with experimental results. In assays with human colorectal adenocarcinoma (Caco-2) cells, a model for the blood–brain barrier (BBB), both chelators were non-toxic, and unlike DFO or 5-ALA-DFO, GABA-DFO was able to bind intracellular iron. Altogether, these results demonstrate that the chemical conjugation proposed here was highly effective and that GABA-DFO is a promising intracellular iron chelator.